Clinical trial
Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection
NCT00197418 · Hamamatsu University, Other · Unknown status
Key facts
| NCT number | NCT00197418 |
|---|---|
| Title | Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection |
| Official title | Dual Therapy With High-Dose of Rabeprazole and Amoxicilline Versus Triple Therapy With Rabeprazole, Amoxicilline and Metronidazole as the Second Line Therapy for the Cure of H. Pylori Infection |
| Lead sponsor | Hamamatsu University, Other |
| Status | Unknown status |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Helicobacter Infections, Gastritis, Gastric Ulcer, Duodenal Ulcer |
| Intervention type | Drug |
| Interventions | rabeprazole, amoxicillin, clarithromycin, metronidazole |
| Start date | Aug 1, 2003 |
| First posted | Sep 20, 2005 |
| Last update posted | Mar 21, 2006 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: